Post-Authorization Study Evaluating Safety Of Tigecycline

CompletedOBSERVATIONAL
Enrollment

115

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Intra-Abdominal InfectionsSkin Disease, InfectiousSoft Tissues Infections
Interventions
DRUG

Tigecycline

Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00827541 - Post-Authorization Study Evaluating Safety Of Tigecycline | Biotech Hunter | Biotech Hunter